Skip to Content

Dolutegravir Dosage

Applies to the following strength(s): 10 mg ; 25 mg ; 50 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for HIV Infection

Therapy-naive or therapy-experienced integrase strand transfer inhibitor (INSTI)-naive patients: 50 mg orally once a day

With concomitant efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, or rifampin: 50 mg orally twice a day

Comments:
-Efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, and rifampin are potent UGT1A/CYP450 3A inducers.

INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance: 50 mg orally twice a day

Comments:
-Alternative combinations that do not include metabolic inducers should be considered where possible.

Usual Pediatric Dose for HIV Infection

12 years or older, weighing at least 40 kg:
Therapy-naive or therapy-experienced INSTI-naive patients: 50 mg orally once a day

With concomitant efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, or rifampin: 50 mg orally twice a day

Comments:
-Safety and efficacy not established in patients younger than 12 years or weighing less than 40 kg.
-Safety and efficacy not established in INSTI-experienced patients with documented or clinically suspected resistance to other INSTIs (raltegravir, elvitegravir).

Renal Dose Adjustments

Therapy-naive or therapy-experienced INSTI-naive patients:
Mild, moderate, or severe renal dysfunction: No adjustment recommended.

INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance):
Mild or moderate renal dysfunction: No adjustment recommended.
Severe renal dysfunction: Caution recommended; loss of therapeutic effect and resistance to this drug or other concomitant antiretroviral agents may occur with decrease in dolutegravir levels.

Liver Dose Adjustments

Mild to moderate liver dysfunction (Child-Pugh A or B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Not recommended.

Precautions

Not recommended in patients younger than 12 years or weighing less than 40 kg.

Consult WARNINGS section for dosing related precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-May be taken without regard to food
-Administer products containing polyvalent cations and supplements containing calcium or iron 6 hours before or 2 hours after this drug; calcium or iron supplements and this drug may be administered together with food.
-Consult the manufacturer product information regarding missed doses.

General:
The following should be considered before starting this drug:
-Poor virologic response was observed in patients treated with dolutegravir 50 mg twice a day with an INSTI-resistance Q148 substitution plus 2 or more additional INSTI-resistance substitutions (including L74I/M, E138A/D/K/T, G140A/S, Y143H/R, E157Q, G163E/K/Q/R/S, or G193E/R).

Monitoring:
-Hepatic: Appropriate laboratory testing (before starting therapy) and monitoring for hepatotoxicity (during therapy) in patients with underlying hepatic disease such as hepatitis B or C

Hide